BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 [PMID: 30581277 DOI: 10.3748/wjg.v24.i46.5288] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Abraham B, Eksteen B, Nedd K, Kale H, Patel D, Stephens J, Shelbaya A, Chambers R, Soonasra A. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Adv Ther 2022;39:2109-27. [PMID: 35296993 DOI: 10.1007/s12325-022-02104-6] [Reference Citation Analysis]
2 Meijboom RW, Gardarsdottir H, Egberts TCG, Giezen TJ. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 2021. [PMID: 34870802 DOI: 10.1007/s40259-021-00508-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res 2021;51:358-73. [DOI: 10.1002/jppr.1754] [Reference Citation Analysis]
5 Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020;34:395-404. [PMID: 32103457 DOI: 10.1007/s40259-020-00409-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Queiroz NSF, Saad-Hossne R, FrÓes RSB, Penna FGCE, Gabriel SB, Martins AL, Teixeira FV. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol 2020;57:232-43. [PMID: 32935741 DOI: 10.1590/S0004-2803.202000000-45] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol 2020;3:234-42. [PMID: 32905124 DOI: 10.1093/jcag/gwz044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Huang J, Ren Y, Wu X, Li Z, Ren J. Gut bioengineering promotes gut repair and pharmaceutical research: a review. J Tissue Eng 2019;10:2041731419839846. [PMID: 31037215 DOI: 10.1177/2041731419839846] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]